In a large clinical trial, Inmazeb showed superiority compared to other investigational agents (ZMapp and remdesivir) with respect to mortality; treatment was most effective when given early in the ...

The United States Food and Drug Administration approved Regeneron Pharmaceuticals, Inc's (NASDAQ: REGN) drug Inmazeb for the treatment of Ebola in both adults and children on Wednesday. What Happened: ...

The FDA has announced its first approval for an Ebola treatment that can be used with both pediatric and adult patients infected by Zaire ebolavirus. The treatment is called Inmazeb; it is comprised ...

The Food and Drug Administration (FDA) announced the first-ever approval of an Ebola drug, which is made of three monoclonal antibodies. The drug, Inmazeb, was developed by Regeneron Pharmaceuticals ...

Developed with the same methods as President Trump’s COVID-19 drug, the antibody cocktail could be a huge leap forward in helping eradicate the deadly virus. Regeneron Pharmaceuticals, Inc. has ...

(RTTNews) - The U.S. Food and Drug Administration has approved Inmazeb, an antibody cocktail made by Regeneron Pharmaceuticals Inc. (REGN), for the treatment of infection caused by Zaire ebolavirus ...

Inmazeb is the first FDA-approved treatment for Zaire ebolavirus TARRYTOWN, N.Y., Oct. 28, 2022 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Inmazeb™ ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Regeneron’s Inmazeb, formerly called REGN-EB3, to treat Zaire ebolavirus infection in adult and ...

The U.S. Food and Drug Administration announced approval Wednesday of the world’s first successful treatment for the Ebola virus, one of the deadliest pathogens on the planet. In this Sunday, July 14, ...

Regeneron will distribute Inmazeb treatment doses over the course of six years to BARDA. Regeneron Pharmaceuticals announced on Oct. 14, 2020 that FDA has approved Inmazeb (atoltivimab, maftivimab, ...